Daily self-administered subcutaneous erythropoietin: benefits in haemodialysis patients.
作者信息
Granolleras C, Branger B, Deschodt G, Shaldon S, Nonnast-Daniel B, Pollok M
机构信息
Department of Nephrology, University Hospital, Nîmes, France.
出版信息
Contrib Nephrol. 1990;82:49-54. doi: 10.1159/000418717.
PMID:2093526
Abstract
摘要
相似文献
1
Daily self-administered subcutaneous erythropoietin: benefits in haemodialysis patients.
Contrib Nephrol. 1990;82:49-54. doi: 10.1159/000418717.
2
Reasons for differences in dose requirements of recombinant human erythropoietin in haemodialysis patients.血液透析患者重组人促红细胞生成素剂量需求差异的原因
Contrib Nephrol. 1990;82:55-64. doi: 10.1159/000418718.
3
Weekly subcutaneous erythropoietin maintains hematocrit in chronic hemodialysis patients.每周皮下注射促红细胞生成素可维持慢性血液透析患者的血细胞比容。
J Am Soc Nephrol. 1993 Apr;3(10):1717-8. doi: 10.1681/ASN.V3101717.
4
Crossover comparison of intravenous and subcutaneous recombinant human erythropoietin in a small haemodialysis unit.小型血液透析单位中静脉注射与皮下注射重组人促红细胞生成素的交叉比较
Nephrol Dial Transplant. 1998 Nov;13(11):2979-80. doi: 10.1093/ndt/13.11.2979.
5
[Utility of recombinant human erythropoietin on the anemia of elderly hemodialysis patients].[重组人促红细胞生成素对老年血液透析患者贫血的效用]
Hinyokika Kiyo. 1992 Dec;38(12):1429-35.
6
Monitoring erythropoietin therapy for anaemia of chronic renal failure by serum erythropoietin assays.通过血清促红细胞生成素检测监测慢性肾衰竭贫血的促红细胞生成素治疗。
Ann Clin Biochem. 1993 Mar;30 ( Pt 2):205-6. doi: 10.1177/000456329303000219.
7
Statement on the clinical use of recombinant erythropoietin in anemia of end-stage renal disease. Ad Hoc Committee for the National Kidney Foundation.关于重组促红细胞生成素在终末期肾病贫血临床应用的声明。美国国家肾脏基金会特设委员会
Am J Kidney Dis. 1989 Sep;14(3):163-9. doi: 10.1016/s0272-6386(89)80066-6.
8
[Correction of anemia in chronic kidney failure with lyophilized recombinant human erythropoietin using a subcutaneous approach].[采用皮下注射法用冻干重组人促红细胞生成素纠正慢性肾衰竭贫血]
Rev Assoc Med Bras (1992). 1994 Apr-Jun;40(2):101-7.
9
Efficacy of once- versus thrice-weekly subcutaneous recombinant human erythropoietin in children receiving continuous cycling peritoneal dialysis.
Am J Nephrol. 1994;14(1):14-8. doi: 10.1159/000168680.
10
Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients.
Nephron. 1993;63(1):113-4. doi: 10.1159/000187156.
引用本文的文献
1
Epoetin: a pharmacoeconomic review of its use in chronic renal failure and its effects on quality of life.促红细胞生成素：关于其在慢性肾衰竭中的应用及其对生活质量影响的药物经济学综述。
Pharmacoeconomics. 1993 Jan;3(1):45-82. doi: 10.2165/00019053-199303010-00006.
2
Low-dosage epoetin in maintenance haemodialysis: costs and quality-of-life improvement.低剂量促红细胞生成素用于维持性血液透析：成本与生活质量改善
Pharmacoeconomics. 1994 Jan;5(1):18-28. doi: 10.2165/00019053-199405010-00004.
Zotero 插件